ImmunoCellular Therapeutics, Ltd. (IMUC)
USD 0.17
(0.06%)
USD 0.17
(0.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.06 Million USD | 37.05% |
| 2022 | -2.43 Million USD | -10.4% |
| 2021 | -1.00 USD | -79.87% |
| 2020 | - USD | 0.0% |
| 2017 | -13.38 Million USD | 13.72% |
| 2016 | -20.2 Million USD | -57.67% |
| 2015 | -12.53 Million USD | -57.91% |
| 2014 | -9.32 Million USD | -4.25% |
| 2013 | -8.8 Million USD | 20.1% |
| 2012 | -14.44 Million USD | -2.71% |
| 2011 | -5.69 Million USD | -179.68% |
| 2010 | -6.14 Million USD | -55.55% |
| 2009 | -2.62 Million USD | 16.68% |
| 2008 | -3.05 Million USD | -267.22% |
| 2007 | -864.39 Thousand USD | 84.25% |
| 2006 | -5.15 Million USD | -3170.86% |
| 2005 | -246 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - USD | 37.05% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q4 | -734.5 Thousand USD | -7.72% |
| 2022 Q3 | -681.88 Thousand USD | -1.27% |
| 2022 Q1 | -795.6 Thousand USD | -31382.09% |
| 2022 Q2 | -673.33 Thousand USD | 15.37% |
| 2022 FY | - USD | -10.4% |
| 2021 Q3 | -5.49 USD | 0.0% |
| 2021 Q1 | -1 Million USD | 0.0% |
| 2021 FY | - USD | -79.87% |
| 2021 Q4 | -2527.15 USD | -45965.46% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2018 Q1 | -1.02 Million USD | -137.98% |
| 2018 Q2 | -306.98 Thousand USD | 70.05% |
| 2017 FY | - USD | 13.72% |
| 2017 Q3 | -3.88 Million USD | 65.68% |
| 2017 Q2 | -11.32 Million USD | -107.47% |
| 2017 Q1 | -5.45 Million USD | 28.67% |
| 2017 Q4 | -430.65 Thousand USD | 88.92% |
| 2016 Q1 | -5.82 Million USD | -9.04% |
| 2016 Q4 | -7.65 Million USD | -37.72% |
| 2016 FY | - USD | -57.67% |
| 2016 Q3 | -5.55 Million USD | -1.54% |
| 2016 Q2 | -5.47 Million USD | 6.12% |
| 2015 FY | - USD | -57.91% |
| 2015 Q1 | -4.85 Million USD | -118.3% |
| 2015 Q3 | -3.73 Million USD | -10.39% |
| 2015 Q4 | -5.34 Million USD | -43.2% |
| 2015 Q2 | -3.38 Million USD | 30.36% |
| 2014 Q1 | -2.33 Million USD | 6.45% |
| 2014 Q3 | -2.42 Million USD | 8.93% |
| 2014 FY | - USD | -4.25% |
| 2014 Q2 | -2.66 Million USD | -14.21% |
| 2014 Q4 | -2.22 Million USD | 8.33% |
| 2013 Q1 | -2.33 Million USD | -5.28% |
| 2013 FY | - USD | 20.1% |
| 2013 Q4 | -2.49 Million USD | -3.31% |
| 2013 Q3 | -2.41 Million USD | -11.41% |
| 2013 Q2 | -2.16 Million USD | 7.05% |
| 2012 Q3 | -3.4 Million USD | -9.19% |
| 2012 Q2 | -3.11 Million USD | -2.64% |
| 2012 FY | - USD | -2.71% |
| 2012 Q1 | -3.03 Million USD | 28.71% |
| 2012 Q4 | -2.21 Million USD | 34.94% |
| 2011 Q4 | -4.25 Million USD | 4.92% |
| 2011 FY | - USD | -179.68% |
| 2011 Q1 | -1.7 Million USD | -1331.89% |
| 2011 Q2 | -2.1 Million USD | -23.07% |
| 2011 Q3 | -4.48 Million USD | -112.99% |
| 2010 Q1 | -754.1 Thousand USD | 11.66% |
| 2010 Q4 | 138.75 Thousand USD | 105.63% |
| 2010 Q3 | -2.46 Million USD | -138.63% |
| 2010 FY | - USD | -55.55% |
| 2010 Q2 | -1.03 Million USD | -37.01% |
| 2009 Q4 | -853.62 Thousand USD | -126.03% |
| 2009 Q1 | -614.11 Thousand USD | 12.21% |
| 2009 Q2 | -799.45 Thousand USD | -30.18% |
| 2009 Q3 | -377.65 Thousand USD | 52.76% |
| 2009 FY | - USD | 16.68% |
| 2008 Q1 | -1.19 Million USD | -233.33% |
| 2008 FY | - USD | -267.22% |
| 2008 Q4 | -699.56 Thousand USD | -18.82% |
| 2008 Q3 | -588.73 Thousand USD | 14.31% |
| 2008 Q2 | -687.05 Thousand USD | 42.72% |
| 2007 FY | - USD | 84.25% |
| 2007 Q4 | -359.83 Thousand USD | -26.81% |
| 2007 Q3 | -283.76 Thousand USD | 67.65% |
| 2007 Q2 | -877.03 Thousand USD | -233.65% |
| 2007 Q1 | 656.23 Thousand USD | 112.62% |
| 2006 FY | - USD | -3170.86% |
| 2006 Q1 | -105.55 Thousand USD | 0.0% |
| 2006 Q2 | -67.14 Thousand USD | 36.39% |
| 2006 Q3 | -103.2 Thousand USD | -53.71% |
| 2006 Q4 | -5.2 Million USD | -4940.34% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.505% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 82.088% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.344% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 93.886% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.129% |
| Mesoblast Limited | -62.38 Million USD | 98.298% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 30.861% |
| Genus plc | 73.7 Million USD | 101.441% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 83.937% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 70.059% |
| Marizyme, Inc. | -34.28 Million USD | 96.902% |
| ContraFect Corporation | -64.99 Million USD | 98.366% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 87.893% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 76.536% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 24.24% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 59.84% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 54.299% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -105.003% |
| Accustem Sciences Inc. | -3.74 Million USD | 71.653% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.798% |
| EV Biologics, Inc. | -1.26 Million USD | 16.188% |
| Q BioMed Inc. | -617.62 Thousand USD | -71.95% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 129.732% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -67.932% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 53.512% |
| Biomind Labs Inc. | -1.03 Million USD | -2.654% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 110.752% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 85.17% |
| Skye Bioscience, Inc. | -13.54 Million USD | 92.161% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 28.6% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -4148.04% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 72.659% |
| IMV Inc. | -35.52 Million USD | 97.01% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 93.308% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 57.553% |
| GB Sciences, Inc. | -1.41 Million USD | 25.205% |
| Alpha Cognition Inc. | -9.7 Million USD | 89.058% |
| HST Global, Inc. | -5303.00 USD | -19926.589% |
| CSL Limited | 4.78 Billion USD | 100.022% |
| Halberd Corporation | -74.27 Thousand USD | -1329.758% |
| Enzolytics Inc. | -2.12 Million USD | 49.953% |
| Resverlogix Corp. | -11.74 Million USD | 90.955% |
| Affymax, Inc. | -14.29 Million USD | 92.571% |
| SYBLEU INC | -141.57 Thousand USD | -650.161% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 65.328% |
| argenx SE | -216.02 Million USD | 99.508% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 98.081% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 187.265% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 29.148% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 380.329% |
| AVAX Technologies, Inc. | -6.11 Million USD | 82.626% |
| Zenith Capital Corp. | -8.6 Million USD | 87.66% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.573% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5996.148% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 56.59% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -503.331% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 97.321% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 63.282% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1.5% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 15894.319% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 39.314% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 44.713% |
| BioStem Technologies, Inc. | -7.55 Million USD | 85.94% |
| ONE Bio Corp. | 13.61 Million USD | 107.801% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -486.461% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 48.371% |
| Agentix Corp. | -1.37 Million USD | 22.58% |
| LadRx Corporation | 412.28 Thousand USD | 357.592% |
| Cell Source, Inc. | -4.27 Million USD | 75.143% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -189.202% |
| Regen BioPharma, Inc. | 1.46 Million USD | 172.445% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -13.348% |
| NovAccess Global Inc. | -1.03 Million USD | -2.63% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 111.995% |
| Itoco Inc. | -1.86 Million USD | 43.177% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -179.756% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 4.838% |
| Kadimastem Ltd | -2.62 Million USD | 59.533% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -344.077% |
| CytoDyn Inc. | -18.02 Million USD | 94.109% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1243.823% |
| Mobile Lads Corp. | -2.24 Million USD | 52.613% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -8584.357% |
| Qrons Inc. | -40.08 Thousand USD | -2549.659% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -118.665% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 301.354% |
| Rebus Holdings, Inc. | -951 Thousand USD | -11.673% |
| International Stem Cell Corporation | 202 Thousand USD | 625.748% |
| Bioxytran, Inc. | -3.82 Million USD | 72.2% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1917.496% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 56.863% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 97.039% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2260.022% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 61.212% |
| Neutra Corp. | -181.24 Thousand USD | -485.946% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 94.732% |
| PureTech Health plc | -11.62 Million USD | 90.866% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 94.731% |
| IXICO plc | -707 Thousand USD | -50.214% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 86.181% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.803% |
| CSL Limited | 4.73 Billion USD | 100.022% |
| Cellectis S.A. | -92.63 Million USD | 98.854% |